Opinion|Videos|July 3, 2024

Improving Access for Patients Receiving CAR T-Cell Therapy

Experts on multiple myeloma provide clinical insights on unmet needs associated with CAR T-cell therapy, focusing on patient access across academic and community settings.

Episodes in this series

Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"

EP. 1 Identifying Potential Candidates for CAR T-Cell Therapy

Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"

EP. 2 Treating Patients Referred to Academic Centers for CAR T

Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"

EP. 3 CAR T-Cell Therapy: Leukapheresis Practices

Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"

EP. 4 Triaging and Prioritizing Patients with Multiple Myeloma

4 KOLs are featured in this program.

EP. 5 Transitioning Patients Back to Community Practices Following CAR T

4 KOLs are featured in this program.

EP. 6 Monitoring Adverse Events Following CAR T-Cell Therapy

4 KOLs are featured in this program.

EP. 7 Educating Patients on Complications Associated with CAR T-Cell Therapy

4 KOLs are featured in this program.

EP. 8 Improving Access for Patients Receiving CAR T-Cell Therapy

A panel of 4 experts on multiple myeloma

EP. 9 Collaborative Education for CAR T-Cell Therapy

EP. 10 Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings

EP. 10 Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings

Dr. Sharma/Dr. Krishnan: What strategies can help community doctors better understand the complications of CAR-T and how do we better coordinate with academic centers to refer back or and which complications can be managed in the community setting?

How can community physicians be trained to recognize and manage CAR-T complications?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.

September 29th, 2026

Where MRD Testing Fits Into Myeloma’s Treatment and Regulatory Landscape

C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.

September 27th, 2026

Applying the IMS/IMWG Definition of Cure in Community Myeloma Practice

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.

September 26th, 2026

Managing Sustained MRD Negativity After Multiple Myeloma Therapy Ends

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

September 25th, 2026

Targeted Agents, Amyloidosis, and Defining a Cure in Plasma Cell Disorders

“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM

September 25th, 2026

Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM

Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.

Rheumatoid arthritis RA in an autoimmune disease faultry activated b cells emitting antibodies which attack the joints causes inflammation front view 3d illustration. with copy space image | Image Credit © vxnaghiyev - stock.adobe.com

September 23rd, 2026

Optimizing Cilta-Cel Sequencing and Community Coordination in Multiple Myeloma

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.

Trending on CancerNetwork

Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer

What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?

Referral Barriers to Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma

SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery

CARTITUDE-2 Cohort A Follow-Up Data and Preparing Patients for CAR TCell Therapy